Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712346 · ClinicalTrials.gov registry record · Phase 1
The Role of Endothelin-1 in Sickle Cell Disease
A Phase 1 study, sponsored by Augusta University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02712346 is a Phase 1 study that has completed, run by Augusta University. The registered enrollment target is 26 participants.
The verdict
NCT02712346, a Phase 1 study, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The primary goal of the study is to determine the safety and tolerability of ambrisentan. It is also expected that ambrisentan will improve blood flow in the lungs, decrease inflammation, and reduce pain in sickle cell patients. An additional goal is to evaluate the use of select biomarkers in evaluating sickle nephropathy.
Interventions
- DRUG Placebo
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02712346
The ClinicalTrials.gov registry entry for NCT02712346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02712346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02712346 about?
NCT02712346 is a clinical study titled "The Role of Endothelin-1 in Sickle Cell Disease". The primary goal of the study is to determine the safety and tolerability of ambrisentan. It is also expected that ambrisentan will improve blood flow in the lungs, decrease inflammation, and reduce pain in sickle cell patients. An additional goal is to evaluate the use of select biomarkers in evalu...
What is the current status of trial NCT02712346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-09. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT02712346?
The interventions under investigation include: Placebo (DRUG), Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT02712346?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.